Collaboration Aims to Improve Actinomycete-Based Pharmaceutical Production - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Collaboration Aims to Improve Actinomycete-Based Pharmaceutical Production

ePT--the Electronic Newsletter of Pharmaceutical Technology

Collaboration Aims to Improve Actinomycete-Based Pharmaceutical Production

The Precision Engineering business unit of Microbia, Inc. (Cambridge, MA) has entered into a research collaboration with the Bioprocessing Technology Institute (BTI, Singapore) to develop a set of metabolic engineering tools for improving the production of secondary metabolites from actinomycete fermentation. Actinomycetes are a broad class of bacteria, and their secondary metabolites are used in various therapeutics such as antibiotics, immunosuppressants, and anticancer agents such as potent cytotoxins.

Although the company will focus on a specific organism and the initial target will be a cancer therapeutic, the company anticipates the techniques and tools developed during the two-year project will be generally applicable to the broad class of antinomycete-based biomanufacturing. “We are focusing on the biology, applying our skills and proprietary techniques to a specific species of bacteria with the anticipation that what we learn will be generally applicable to any actinomycete fermentation,” says Kevin Madden, senior director of Precision Engineering.

Microbia’s set of metabolic profiling tools, including microarray technologies, transcriptional profiling, and informatic approaches, will identify those genes that are critical for optimal metabolite production. The company previously applied these techniques to industrial strains of fungi. “The problems with industrial fungi very much parallel the engineering challenges with actinomycetes in that molecular biology tools really have not worked all that well when trying to improve the volumetric productivity of the commercial strains,” says Madden.

–Maribel Rios

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here